1-10 of 10
Deborah Thomas
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Naval Daver, Yanis Boumber, Hagop Kantarjian, Farhad Ravandi, Jorge Cortes, Michael E. Rytting, Jitesh D. Kawedia, Jordan Basnett, Kirk S. Culotta, Zhihong Zeng, Hongbo Lu, Mary Ann Richie, Rebecca Garris, Lianchun Xiao, Wenbin Liu, Keith A. Baggerly, Elias Jabbour, Susan O'Brien, Jan Burger, Linda J. Bendall, Deborah Thomas, Marina Konopleva
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (12): 2704–2714.
https://doi.org/10.1158/1078-0432.CCR-14-2888
Published: 14 June 2015
View article titled, A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Open the PDF for A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia in another window
Includes: Supplementary data
Journal Articles

Circulating Ki-67 protein as a biomarker and prognostic indicator of acute lymphoblastic leukemia

Jean-Marie Bruey, Hagop Kantarjian, Wanlong Ma, Deborah Thomas, Francis Giles, Maher Albitar
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (19_Supplement): B36.
Published: 15 August 2014
View article titled, Circulating Ki-67 protein as a biomarker and prognostic indicator of acute lymphoblastic leukemia
Journal Articles

Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis

Srdan Verstovsek, Ayalew Tefferi, Jorge Cortes, Susan O'Brien, Guillermo Garcia-Manero, Animesh Pardanani, Cem Akin, Stefan Faderl, Taghi Manshouri, Deborah Thomas, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (12): 3906–3915.
https://doi.org/10.1158/1078-0432.CCR-08-0366
Published: 16 June 2008
View article titled, Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis
Open the PDF for Phase II Study of Dasatinib in Philadelphia Chromosome–Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis in another window
Journal Articles

Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies

Karen W.L. Yee, Zhihong Zeng, Marina Konopleva, Srdan Verstovsek, Farhad Ravandi, Alessandra Ferrajoli, Deborah Thomas, William Wierda, Efrosyni Apostolidou, Maher Albitar, Susan O'Brien, Michael Andreeff, Francis J. Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (17): 5165–5173.
https://doi.org/10.1158/1078-0432.CCR-06-0764
Published: 01 September 2006
View article titled, Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies
Open the PDF for Phase I/II Study of the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) in Patients with Relapsed or Refractory Hematologic Malignancies in another window
Journal Articles

Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia

Francis Giles, Srdan Verstovsek, Deborah Thomas, Stanton Gerson, Jorge Cortes, Stefan Faderl, Alessandra Ferrajoli, Farhad Ravandi, Steven Kornblau, Guillermo Garcia-Manero, Elias Jabbour, Susan O'Brien, Verena Karsten, Ann Cahill, Karen Yee, Maher Albitar, Mario Sznol, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7817–7824.
https://doi.org/10.1158/1078-0432.CCR-05-1070
Published: 08 November 2005
View article titled, Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia
Open the PDF for Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia in another window
Journal Articles

Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies

Karen W.L. Yee, Anne Hagey, Srdan Verstovsek, Jorge Cortes, Guillermo Garcia-Manero, Susan M. O'Brien, Stefan Faderl, Deborah Thomas, William Wierda, Steven Kornblau, Alessandra Ferrajoli, Maher Albitar, Evelyn McKeegan, David R. Grimm, Toby Mueller, Rhonda R. Holley-Shanks, Leonardo Sahelijo, Gary B. Gordon, Hagop M. Kantarjian, Francis J. Giles
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (18): 6615–6624.
https://doi.org/10.1158/1078-0432.CCR-05-0650
Published: 15 September 2005
View article titled, Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies
Open the PDF for Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies in another window
Journal Articles

Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias

Jorge Cortes, Deborah Thomas, Charles Koller, Francis Giles, Elihu Estey, Stefan Faderl, Guillermo Garcia-Manero, David McConkey, Gira Patel, Roberto Guerciolini, John Wright, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (10): 3371–3376.
https://doi.org/10.1158/1078-0432.CCR-03-0508
Published: 24 May 2004
View article titled, Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias
Open the PDF for Phase I Study of Bortezomib in Refractory or Relapsed Acute Leukemias in another window
Journal Articles

A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia

Francis Giles, Deborah Thomas, Guillermo Garcia-Manero, Stefan Faderl, Jorge Cortes, Srdan Verstovsek, Alessandra Ferrajoli, Sima Jeha, Miloslav Beran, Charles Koller, Michael Andreeff, Ann Cahill, Caroline Clairmont, Mario Sznol, Hagop Kantarjian
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (9): 2908–2917.
https://doi.org/10.1158/1078-0432.CCR-03-0738
Published: 06 May 2004
View article titled, A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia
Open the PDF for A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia in another window
Journal Articles

Quantitative Polymerase Chain Reaction Monitoring of BCR-ABL during Therapy with Imatinib Mesylate (STI571; Gleevec) in Chronic-Phase Chronic Myelogenous Leukemia

Hagop M. Kantarjian, Moshe Talpaz, Jorge Cortes, Susan O’Brien, Stefan Faderl, Deborah Thomas, Francis Giles, Mary Beth Rios, Jianqin Shan, Ralph Arlinghaus
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (1): 160–166.
Published: 01 January 2003
View article titled, Quantitative Polymerase Chain Reaction Monitoring of <em>BCR-ABL</em> during Therapy with Imatinib Mesylate (STI571; Gleevec) in Chronic-Phase Chronic Myelogenous Leukemia
Open the PDF for Quantitative Polymerase Chain Reaction Monitoring of <em>BCR-ABL</em> during Therapy with Imatinib Mesylate (STI571; Gleevec) in Chronic-Phase Chronic Myelogenous Leukemia in another window
Journal Articles

The Prognostic Significance of p16INK4a/p14ARF and p15INK4b Deletions in Adult Acute Lymphoblastic Leukemia

Stefan Faderl, Hagop M. Kantarjian, Taghi Manshouri, Chin-Yung Chan, Sherry Pierce, Kimberly J. Hays, Jorge Cortes, Deborah Thomas, Zeev Estrov, Maher Albitar
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (7): 1855–1861.
Published: 01 July 1999
View article titled, The Prognostic Significance of <em>p16</em><sup><em>INK4a</em></sup>/<em>p14</em><sup><em>ARF</em></sup> and <em>p15</em><sup><em>INK4b</em></sup> Deletions in Adult Acute Lymphoblastic Leukemia
Open the PDF for The Prognostic Significance of <em>p16</em><sup><em>INK4a</em></sup>/<em>p14</em><sup><em>ARF</em></sup> and <em>p15</em><sup><em>INK4b</em></sup> Deletions in Adult Acute Lymphoblastic Leukemia in another window